Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Eustace, Amanda, Irlam, Joely J., Taylor, Janet, Denley, Helen, Agrawal, Shailesh, Choudhury, Ananya, Ryder, David, Ord, Jonathan J., Harris, Adrian L., Rojas, Ana M., Hoskin, Peter J., West, Catharine M.L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Scientific Publishers 2013
Soggetti:
Phase III randomised trial
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://ncbi.nlm.nih.gov/pubmed/23773411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2013.05.017
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi